Explanipedia

Does Changing the Game Metaphor Change the Assessment? Open

Y.-D. Zhou, You Zhi Hu, Zhaolin Xu, Jianrong Wu, Mark Chignell · 2025

This study examined whether altering the metaphor—or visual skin—of a cognitive assessment game affects its psychometric properties. BrainTagger is a suite of serious games used to assess executive functions such as processing speed, respo…

Comparing and Contrasting N-Back and Self-Directed Memory Selection, as Measures of Working Memory Open

Y.-D. Zhou, You Zhi Hu, Zhaolin Xu, Jianrong Wu, Mark Chignell · 2025

Working memory (WM) is a fundamental cognitive function, yet different tasks may assess distinct aspects of WM. We investigated the relationship between self-directed selection from memory sets and performance on the N-back task. One hundr…

Inhibiting the Interaction Between Phospholipase A2 and Phospholipid Serine as a Potential Therapeutic Method for Pneumonia Open

Jianyu Wang, Huanchun Xing, Lin Wang, Zhaolin Xu, Xin Sui , et al. · 2025

Pneumonia is a severe lower respiratory tract infection. This study demonstrates that phospholipase A2 (PLA2), a potential biomarker for pneumonia, contributes to alveoli damage by hydrolyzing pulmonary surfactant phospholipids. This proce…

Identification of Driver Mutations and Risk Stratification in Lung Adenocarcinoma via Liquid Biopsy Open

Gopal P. Pathak, Rashmi R. Shah, Tony Reiman, Alison Wallace, Michael D. Carter , et al. · 2025

Background: Liquid biopsy using plasma cfDNA has been established as a tool for informing the management of advanced-stage NSCLC. However, its effectiveness in early lung cancer detection, including the identification of high-risk cases, r…

Screening Criteria Evaluation for Expansion in Pulmonary Neoplasias (SCREEN) II Open

Bright Huo, Katerina‐Maria Kontouli, Daria Manos, Zhaolin Xu, Samuel Chun , et al. · 2025

Les personnes dont le tabagisme est léger voire nul qui ne sont pas admissibles au dépistage ont présenté un taux plus élevé de cancer du poumon EGFRet PIK3CA-positifs comparativement aux gros fumeurs, lorsqu'on appliquait le…

Temporal Effect on PD‐L1 Detection and Novel Insights Into Its Clinical Implications in Non–Small Cell Lung Cancer Open

Gopal P. Pathak, Rashmi R. Shah, Mathieu Castonguay, Angela Cheng, John Fris , et al. · 2024

Objectives Several studies rely on archived tissue blocks to assess the PD‐L1 scores; however, a detailed analysis of potential variations of scores between fresh and archived tissue blocks still lacks. In addition, the prognostic implicat…

Canadian Multicentric Pan-TRK (CANTRK) Immunohistochemistry Harmonization Study Open

Martin Hyrcza, Sebastião N. Martins-Filho, Alan Spatz, Hanjun Wang, Bibianna Purgina , et al. · 2023

Tumor-agnostic testing for NTRK1-3 gene rearrangements is required to identify patients who may benefit from TRK inhibitor therapies. The overarching objective of this study was to establish a high-quality pan-TRK immunohistochemistry (IHC…

Genistein and Procyanidin B2 Reduce Carcinogen-Induced Reactive Oxygen Species and DNA Damage through the Activation of Nrf2/ARE Cell Signaling in Bronchial Epithelial Cells In Vitro Open

Tharindu L. Suraweera, J. P. Jose Merlin, Graham Dellaire, Zhaolin Xu, H.P. Vasantha Rupasinghe · 2023

Cancer is one of the leading causes of death worldwide. Chemotherapy and radiation therapy are currently providing the basis for cancer therapies, although both are associated with significant side effects. Thus, cancer prevention through …

Consensus Recommendations to Optimize Testing for New Targetable Alterations in Non-Small Cell Lung Cancer Open

Diana N. Ionescu, Tracy Stockley, Shantanu Banerji, Christian Couture, Cheryl A. Mather , et al. · 2022

Non-small cell lung cancer (NSCLC) has historically been associated with a poor prognosis and low 5-year survival, but the use of targeted therapies in NSCLC has improved patient outcomes over the past 10 years. The pace of development of …

Lung-Protective Ventilation Attenuates Mechanical Injury While Hypercapnia Attenuates Biological Injury in a Rat Model of Ventilator-Associated Lung Injury Open

Nada Ismaiel, Sara Whynot, Laurette Geldenhuys, Zhaolin Xu, Arthur S. Slutsky , et al. · 2022

Background and Objective: Lung-protective mechanical ventilation is known to attenuate ventilator-associated lung injury (VALI), but often at the expense of hypoventilation and hypercapnia. It remains unclear whether the main mechanism by …

Konsensusempfehlungen zur Optimierung von Tests auf neue geeignete Zielmutationen bei nicht kleinzelligem Lungenkrebs Open

Diana Beşliu-Ionescu, Tracy Stockley, Shantanu Banerji, Christian Couture, Cheryl A. Mather , et al. · 2022

Ein nicht kleinzelliges Lungenkarzinom (NSCLC) wird seit jeher mit einer schlechten Prognose und einer geringen Überlebensrate von bis zu 5 Jahren in Verbindung gebracht, aber der Einsatz zielgerichteter Therapien beim NSCLC hat die Behand…

Evaluating Targeted Next-Generation Sequencing Assays and Reference Materials for NTRK Fusion Detection Open

Christina Bormann Chung, Jeeyun Lee, Marc Barritault, Pierre‐Paul Bringuier, Zhaolin Xu , et al. · 2021

Neurotrophic tyrosine receptor kinase (NTRK1/2/3) fusions are oncogenic drivers in approximately 0.3% of solid tumors. High-quality testing to identify patients with NTRK fusion-positive tumors who could benefit from tropomyosin receptor k…

Single-cell RNA sequencing for the identification of early-stage lung cancer biomarkers from circulating blood Open

Jin-Hong Kim, Zhaolin Xu, Paola A. Marignani · 2021

Profiling non-small cell lung cancer reveals that PD-L1 is associated with wild type EGFR and vascular invasion, and immunohistochemistry quantification of PD-L1 correlates weakly with RT-qPCR Open

Akram Alwithenani, Drew Bethune, Mathieu Castonguay, Arik Drucker, Gordon Flowerdew , et al. · 2021

Most lung cancer patients are diagnosed at an advanced stage, limiting their treatment options with very low response rate. Lung cancer is the most common cause of cancer death worldwide. Therapies that target driver gene mutations (e.g. E…

Diffuse Pulmonary Ossification Diagnosed by Transbronchial Biopsy: A Case Report Open

Teresa Rodríguez, Daria Manos, Zhaolin Xu, Simon Houston · 2021

MET Exon 14 Skipping Alterations in Non-small Cell Lung Carcinoma—Current Understanding and Therapeutic Advances Open

Rashmi R. Shah, Deepu Alex, Zhaolin Xu · 2021

Regulation of Nrf2/ARE Pathway by Dietary Flavonoids: A Friend or Foe for Cancer Management? Open

Tharindu L. Suraweera, H.P. Vasantha Rupasinghe, Graham Dellaire, Zhaolin Xu · 2020

The nuclear factor erythroid 2-related factor 2 (Nrf2)/antioxidant response element (ARE) pathway is an important cell signaling mechanism in maintaining redox homeostasis in humans. The role of dietary flavonoids in activating Nrf2/ARE in…

Canadian Multicenter Project on Standardization of Programmed Death-Ligand 1 Immunohistochemistry 22C3 Laboratory-Developed Tests for Pembrolizumab Therapy in NSCLC Open

Emina Torlakovic, Roula Albadine, Gilbert Bigras, Alexander H. Boag, Anna Bojarski , et al. · 2020

It is possible to harmonize highly accurate 22C3 LDTs for both 1% and 50% tumor proportion score in NSCLC across many laboratories with different platforms. However, despite a centralized approach, diagnostic validation of predictive IHC L…

Epithelial tumor suppressor ELF3 is a lineage-specific amplified oncogene in lung adenocarcinoma Open

Katey S.S. Enfield, Erin A. Marshall, Thomas Anderson, Kevin W. Ng, Sara Rahmati , et al. · 2019

Increased effort during partial ventilatory support is not associated with lung damage in experimental acute lung injury Open

Dietrich Henzler, A. Schmidt, Zhaolin Xu, Nada Ismaiel, Haibo Zhang , et al. · 2019

Fit-For-Purpose PD-L1 Biomarker Testing For Patient Selection in Immuno-Oncology: Guidelines For Clinical Laboratories From the Canadian Association of Pathologists-Association Canadienne Des Pathologistes (CAP-ACP) Open

Carol C. Cheung, Penny J. Barnes, Gilbert Bigras, Scott Boerner, Jagdish Butany , et al. · 2019

Since 2014, programmed cell death protein 1 (PD-1)/programmed cell death ligand 1 (PD-L1) checkpoint inhibitors have been approved by various regulatory agencies for the treatment of multiple cancers including melanoma, lung cancer, urothe…

“Interchangeability” of PD-L1 immunohistochemistry assays: a meta-analysis of diagnostic accuracy Open

Emina Torlakovic, Hyun J. Lim, Julien Adam, Penny J. Barnes, Gilbert Bigras , et al. · 2019

Crizotinib Inhibition of ROS1-Positive Tumours in Advanced Non-Small-Cell Lung Cancer: A Canadian Perspective Open

D.G. Bebb, Jason Agulnik, Roula Albadine, Shantanu Banerji, Gilbert Bigras , et al. · 2019

The ROS1 kinase is an oncogenic driver in non-small-cell lung cancer (NSCLC). Fusion events involving the ROS1 gene are found in 1%–2% of NSCLC patients and lead to deregulation of a tyrosine kinase–mediated multi-use intracellular signall…

P3.03-02 Single-Cell RNA-Seq in Human Lung Cancer Open

J. Kim, Zhaolin Xu, Paola A. Marignani · 2018

Canadian Perspectives: Update on Inhibition of ALK-Positive Tumours in Advanced Non-Small-Cell Lung Cancer Open

Barbara Melosky, Parneet Cheema, Jason Agulnik, Roula Albadine, D. Gwyn Bebb , et al. · 2018

Background: Inhibition of the anaplastic lymphoma kinase (ALK) oncogenic driver in advanced non-small-cell lung carcinoma (NSCLS) improves survival. In 2015, Canadian thoracic oncology specialists published a consensus guideline about the …

OA08.07 In Silico Discovery of Unannotated miRNAs in Malignant Pleural Mesothelioma Reveals Novel Tissue-of-Origin Markers Open

Brenda C. Minatel, Erin A. Marshall, C. Anderson, Ka‐Lok Ng, Katey S.S. Enfield , et al. · 2018

RTN4 Knockdown Dysregulates the AKT Pathway, Destabilizes the Cytoskeleton, and Enhances Paclitaxel-Induced Cytotoxicity in Cancers Open

Gopal P. Pathak, Rashmi R. Shah, Barry E. Kennedy, J. Patrick Murphy, Derek R. Clements , et al. · 2018

Standardizing Biomarker Testing for Canadian Patients with Advanced Lung Cancer Open

Barbara Melosky, Normand Blais, Parneet Cheema, Christian Couture, Rosalyn A. Juergens , et al. · 2018

Background: The development and approval of both targeted and immune therapies for patients with advanced non-small cell lung cancer (NSCLS) has significantly improved patient survival rates and quality of life. Biomarker testing for patie…

OA 15.01 Lung Cancer Screening: Participant Selection by Risk Model – the Pan-Canadian Study Open

Martin C. Tammemägi, Heidi Schmidt, Simon Martel, Annette McWilliams, John R. Goffin , et al. · 2017

Loss of PRP4K drives anoikis resistance in part by dysregulation of epidermal growth factor receptor endosomal trafficking Open

Dale Corkery, Livia E. Clarke, Simon Gebremeskel, Jayme Salsman, Jordan Pinder , et al. · 2017

Zhaolin Xu YOU? Author Swipe